Pancreatic cancer drug Daraxonrasib gets approval from FDA: All you need to know
FDA officials gave expedited approval to daraxonrasib, which blocks a mutated protein that fuels tumor growth
The FDA has approved a new drug, daraxonrasib, for advanced pancreatic cancer, marking a significant breakthrough in treating one of the deadliest forms of cancer. The pill, sold under the brand name Rasonque by Revolution Medicines, targets mutated proteins that fuel tumor growth in over 90% of pancreatic cancer cases. In a study, patients taking the drug showed nearly double the survival time compared to those receiving chemotherapy, with fewer severe side effects.
The drug, which costs about $39,800 for a one-month supply, is particularly noteworthy as pancreatic cancer has been notoriously difficult to treat due to its late detection and the "undruggable" nature of its underlying mutations. This approval not only offers a more effective treatment option for patients but also paves the way for other drugs targeting similar genetic mutations in various cancers.
Brief written by urgent.news from Hindustan Times - World News's own syndicated text. Machine-written — may contain errors; check the original before relying on it.
This story
This is one outlet's version. Read the fullest account.
